Back to results
Bibliographic record · Consultation and access
Artículo

The Clinical Outcomes of Tocilizumab Usage in Cryptogenic Febrile Infection-Related Epilepsy Syndrome at Both Acute and Chronic Phase: A Retrospective Study

Deng X et al · Dove Medical Press · 2026

Open-access full text
Quick overview. Review the resource’s basic details, then access the content using the main button. This page shows only the information needed to identify, cite, and open the work.

Resource access

Open the content from the main option or choose another available source.

DOAJ DOAJ Articles
Entrar por DOAJ
Main access

Open-access full text

Texto completo identificado como acceso abierto.
Open text
Otras opciones de acceso Elegí el proveedor disponible para esta ficha.
DOAJ CSV Export DOAJ - Open Access Journals
Acceder por DOAJ CSV Export
DOAJ OAI-PMH DOAJ Articles
Acceder por DOAJ OAI-PMH
Importación CSV DOAJ - Open Access Journals
Acceder por Importación CSV

Other available options

When the resource is available on more than one platform, you can choose where to open it.

DOAJ CSV Export DOAJ - Open Access Journals Access available
Open
DOAJ OAI-PMH DOAJ Articles Access available
Open
Importación CSV DOAJ - Open Access Journals Access available
Open

Summary

Descripción general del contenido del recurso.

Xiaolu Deng,1,2 Shimeng Chen,1,2 Fei Yin,1,2 Fang He,1,2 Ciliu Zhang,1,2 Lifen Yang,1,2 Leilei Mao,1,2 Li Yang,1,2 Yang Han,1,2 Jing Peng1,2 1Department of Pediatrics, Xiangya Hospital, Central South University, Changsha, 410000, People’s Republic of China; 2Clinical Research Center for Children Neurodevelopmental Disabilities of Hunan Province, Xiangya Hospital, Central South University, Changsha, 410000, People’s Republic of ChinaCorrespondence: Jing Peng, Email pengjing627@126.comPurpose: To provide more observational evidence for potential efficacy of tocilizumab (TCZ) in children with cryptogenic febrile infection-related epilepsy syndrome (FIRES) administered during acute and chronic phase.Methods: Data of 22 children with FIRES who received TCZ were collected retrospectively. Patients were categorized into two groups: acute group (TCZ used within 4 weeks post-onset; n = 12) and chronic group (TCZ used beyond 4 weeks post-onset; n = 10).Results: In both groups, patients experienced > 50% reduction in seizure frequency, electroencephalogram (EEG) improvements, alleviation on cranial magnetic resonance imaging (MRI), and significantly decreased mRS scores (P < 0.05). In acute group, 6 patients became seizure-free by the last follow-up, and 7 patients reduced their number of antiseizure medications (ASMs). TCZ administration in acute phase shortened status epilepticus (SE) duration. At last follow-up, the acute group exhibited higher rates of seizure freedom and > 50% seizure reduction (P < 0.05), lower incidences of motor and speech deficits (P < 0.05), and a greater likelihood of returning to school (P < 0.05).Conclusion: TCZ treatment was associated with reduced seizure frequency, improved EEG and MRI findings, decreased reliance on antiseizure medications, and functional improvement as measured by mRS. Initiation of treatment during the acute phase may be associated with a shortened duration of status epilepticus and, compared to chronic-phase intervention, appears to correlate with more favorable long-term outcomes.Keywords: FIRES, TCZ, outcomes, chronic phase, acute phase

How to cite

Elegí el formato que necesitás y copiá la referencia al portapapeles.

APA 7

al, D. X. E. (2026). The Clinical Outcomes of Tocilizumab Usage in Cryptogenic Febrile Infection-Related Epilepsy Syndrome at Both Acute and Chronic Phase: A Retrospective Study. https://www.dovepress.com/the-clinical-outcomes-of-tocilizumab-usage-in-cryptogenic-febrile-infe-peer-reviewed-fulltext-article-JIR

MLA

al, Deng X et. "The Clinical Outcomes of Tocilizumab Usage in Cryptogenic Febrile Infection-Related Epilepsy Syndrome at Both Acute and Chronic Phase: A Retrospective Study." 2026. https://www.dovepress.com/the-clinical-outcomes-of-tocilizumab-usage-in-cryptogenic-febrile-infe-peer-reviewed-fulltext-article-JIR.

Chicago

al, Deng X et. 2026. "The Clinical Outcomes of Tocilizumab Usage in Cryptogenic Febrile Infection-Related Epilepsy Syndrome at Both Acute and Chronic Phase: A Retrospective Study.". https://www.dovepress.com/the-clinical-outcomes-of-tocilizumab-usage-in-cryptogenic-febrile-infe-peer-reviewed-fulltext-article-JIR.

Harvard

al, D. X. E. 2026, The Clinical Outcomes of Tocilizumab Usage in Cryptogenic Febrile Infection-Related Epilepsy Syndrome at Both Acute and Chronic Phase: A Retrospective Study, Dove Medical Press, available at: https://www.dovepress.com/the-clinical-outcomes-of-tocilizumab-usage-in-cryptogenic-febrile-infe-peer-reviewed-fulltext-article-JIR [Accessed 8 Aug. 2026].

Share and print

Save the record, copy its permanent link, or print it as a PDF.

Export reference

You can export the record in common formats for use in a reference manager.

Resource details

Bibliographic information to help confirm that this is the correct material.

Title
The Clinical Outcomes of Tocilizumab Usage in Cryptogenic Febrile Infection-Related Epilepsy Syndrome at Both Acute and Chronic Phase: A Retrospective Study
Author / contributors
Deng X et al
Publisher
Dove Medical Press
Publication year
2026
ISSN
1178-7031
ISSN
1178-7031
Language
English

Subjects

Explore related resources through these subjects.

Copied